Conference Roundup

Von Willebrand Disease Phase III Clinical Trial Announced

Posted on

A clinical trial aimed at determining if intravenous recombinant von Willebrand factor (rVWF) is more effective than the current non-hormonal standard oral tranexamic acid in reducing menorrhagia in women with von Willebrand disease was announced at the 2019 American Society of Hematology annual meeting.

To watch the video of study author Margaret Ragni, MD, of UPMC Hillman Cancer Center discussing the study results, click here.  

Related Articles
Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment
Jun 01, 2021
ASH: Novel Fetal Hemoglobin Repressor for Sickle Cell Disease Identified
May 31, 2020
Education and Support Enhance Care for Rare-Disease Patients
Mar 27, 2020